155 related articles for article (PubMed ID: 28261348)
1. Epigenetic dysregulation of
Li XX; Zhou JD; Zhang TJ; Yang L; Wen XM; Ma JC; Yang J; Zhang ZH; Lin J; Qian J
J Cancer; 2017; 8(3):460-468. PubMed ID: 28261348
[No Abstract] [Full Text] [Related]
2. Decreased SCIN expression, associated with promoter methylation, is a valuable predictor for prognosis in acute myeloid leukemia.
Zhang ZH; Zhang W; Zhou JD; Zhang TJ; Ma JC; Xu ZJ; Lian XY; Wu DH; Wen XM; Deng ZQ; Lin J; Qian J
Mol Carcinog; 2018 Jun; 57(6):735-744. PubMed ID: 29457658
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
Lian XY; Ma JC; Zhou JD; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Li XX; He PF; Yan Y; Lin J; Qian J
J Cell Physiol; 2019 Jun; 234(6):9438-9446. PubMed ID: 30317626
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
[TBL] [Abstract][Full Text] [Related]
5. Methylation-associated DOK1 and DOK2 down-regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia.
He PF; Xu ZJ; Zhou JD; Li XX; Zhang W; Wu DH; Zhang ZH; Lian XY; Yao XY; Deng ZQ; Lin J; Qian J
J Cell Physiol; 2018 Sep; 233(9):6604-6614. PubMed ID: 29150948
[TBL] [Abstract][Full Text] [Related]
6. Methylation-independent
Ma BB; Zhang TJ; Wang CZ; Xu ZJ; Zhou JD; Gu Y; Ma JC; Deng ZQ; Lin J; Qian J
Am J Transl Res; 2020; 12(9):4840-4852. PubMed ID: 33042393
[TBL] [Abstract][Full Text] [Related]
7. Abnormal expression and methylation of PRR34-AS1 are associated with adverse outcomes in acute myeloid leukemia.
Nan FY; Gu Y; Xu ZJ; Sun GK; Zhou JD; Zhang TJ; Ma JC; Leng JY; Lin J; Qian J
Cancer Med; 2021 Aug; 10(15):5283-5296. PubMed ID: 34227248
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of secreted frizzled-related proteins predicts poor prognosis in non-M3 acute myeloid leukemia.
Guo H; Zhang TJ; Wen XM; Zhou JD; Ma JC; An C; Zhang W; Xu ZJ; Lin J; Qian J
Onco Targets Ther; 2017; 10():3635-3644. PubMed ID: 28790854
[TBL] [Abstract][Full Text] [Related]
9. DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.
Zhou JD; Zhang TJ; Wang YX; Yang DQ; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
Tumour Biol; 2016 Jul; 37(7):8951-60. PubMed ID: 26753961
[TBL] [Abstract][Full Text] [Related]
10. GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.
Zhou JD; Yao DM; Zhang YY; Ma JC; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
Am J Cancer Res; 2015; 5(5):1786-94. PubMed ID: 26175946
[TBL] [Abstract][Full Text] [Related]
11. GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia.
Zhou JD; Yao DM; Zhang YY; Ma JC; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
Am J Cancer Res; 2015; 5(6):2047-55. PubMed ID: 26269763
[TBL] [Abstract][Full Text] [Related]
12. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
[TBL] [Abstract][Full Text] [Related]
13. Methylation-independent ITGA2 overexpression is associated with poor prognosis in de novo acute myeloid leukemia.
Lian XY; Zhang W; Wu DH; Ma JC; Zhou JD; Zhang ZH; Wen XM; Xu ZJ; Lin J; Qian J
J Cell Physiol; 2018 Dec; 233(12):9584-9593. PubMed ID: 30132837
[TBL] [Abstract][Full Text] [Related]
14. DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia.
Zhang YY; Yao DM; Zhu XW; Zhou JD; Ma JC; Yang J; Wen XM; Guo H; Lin J; Qian J
Leuk Res; 2015 Oct; 39(10):1041-7. PubMed ID: 26242829
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine.
Tang LJ; Sun GK; Zhang TJ; Wu DH; Zhou JD; Ma BB; Xu ZJ; Wen XM; Chen Q; Yao DM; Qian J; Ma JC; Lin J
Cancer Cell Int; 2019; 19():177. PubMed ID: 31333331
[TBL] [Abstract][Full Text] [Related]
16. Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Qian Z; Wen XM; Zhou JD; Li XX; Xu ZJ; Ma JC; Zhang ZH; Lin J; Qian J
Pathol Res Pract; 2018 Jun; 214(6):896-901. PubMed ID: 29627222
[TBL] [Abstract][Full Text] [Related]
17. Increased
Li XX; Zhou JD; Wen XM; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Lian XY; He PF; Yao XY; Lin J; Qian J
Onco Targets Ther; 2019; 12():3295-3304. PubMed ID: 31118680
[No Abstract] [Full Text] [Related]
18. The 5' flanking region of miR-378 is hypomethylated in acute myeloid leukemia.
Zhu XW; Wen XM; Zhang YY; Yang L; Guo H; Yang J; Zhang M; Yin JY; Ma JC; Lin J; Deng ZQ; Qian J
Int J Clin Exp Pathol; 2015; 8(5):4321-31. PubMed ID: 26191124
[TBL] [Abstract][Full Text] [Related]
19. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.
Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J
J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158
[TBL] [Abstract][Full Text] [Related]
20. Low expression of microRNA-340 confers adverse clinical outcome in patients with acute myeloid leukemia.
Wang Q; Feng T; Xu J; Miao MH; Ji XQ; Zhu H; Shao XJ
J Cell Physiol; 2019 Apr; 234(4):4200-4205. PubMed ID: 30171606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
